HBK Sorce Advisory LLC Acquires New Shares in Becton, Dickinson and Company $BDX

HBK Sorce Advisory LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, Holdings Channel reports. The institutional investor acquired 3,036 shares of the medical instruments supplier’s stock, valued at approximately $518,000.

Several other hedge funds also recently bought and sold shares of BDX. Flputnam Investment Management Co. purchased a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $1,525,000. Global Retirement Partners LLC purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $1,178,000. 1ST Source Bank acquired a new position in Becton, Dickinson and Company in the 2nd quarter valued at about $218,000. Bank of New York Mellon Corp purchased a new stake in Becton, Dickinson and Company during the second quarter worth about $247,372,000. Finally, Focus Partners Advisor Solutions LLC purchased a new stake in Becton, Dickinson and Company during the second quarter worth about $200,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. This represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 11,779 shares of company stock worth $1,974,669. 0.40% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Bank of America lowered their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. UBS Group started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. Barclays lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, TD Cowen boosted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Stock Down 0.6%

Shares of NYSE BDX opened at $182.39 on Tuesday. The stock has a market capitalization of $50.26 billion, a price-to-earnings ratio of 54.94, a price-to-earnings-growth ratio of 12.93 and a beta of 0.19. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The firm has a 50-day moving average price of $158.48 and a 200 day moving average price of $161.26. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the business earned $3.68 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.